Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2020 | Story Eugene Seegers | Photo Sonia du Toit/Kaleidoscope Studios
Dr Marinkie Madiope looks up to her mother as an inspirational woman.

Dr Maria ‘Marinkie’ Madiope is not your average professional woman. Her academic record speaks of vigilant style and resilient independence. The challenge of discovery, innovation, and stretching herself and everyone around her are qualities she values. The University of the Free State benefits from the extraordinary energy that characterises this woman. She is an infectious team leader, spurring others on to ever-greater heights, and is always on the lookout for something she can do for others: whether it is large-scale advocacy for women or smaller acts of empowerment. She describes herself as an “ever-present mother and sister” to those with whom she works. It is humbling to watch her Ubuntu in action. 

Please tell us about yourself

“My academic interests lie in the realm of ICT and curriculum design and development, which is what drew me to working on the South Campus. Open, Distance, and eLearning (ODeL) is also close to my heart, and I have been the editor of Progressio, the only ODeL journal in South Africa, since 2016.

My expertise in eLearning is another of my strengths; I designed the Unisa online ethics course, which was launched in Geneva in 2015 and is currently being offered internationally in collaboration with Ethics SA. 

As part of community engagement, I take part in the Africa Crèche Project to empower women. I enjoy working with young minds and little humans to provide them opportunities to which they otherwise would not have access.”

What do you do at the university?

“I am currently the Principal of the South Campus in Bloemfontein. The South Campus is dedicated to delivering quality distance education to sectors of society that would not necessarily have access to higher education. It advances education through ODeL delivery modes.

 

It is … vital to avoid dwelling on past mistakes, because regret robs you of joy. - Dr Maria Madiope, Principal: UFS South Campus.


“I enjoy the opportunity to transform the Open Distance Learning campus of the UFS to a digitised university.  I cannot express the feelings I have when welcoming students to the UFS to unlock their future, or when they graduate. Especially students who have gone through very traumatic home, personal, or academic times. They still succeed, even when others have given up on them.”

What advice would you give to a 15-year-old you?

“I see women as proud warriors — resilient and strong guardians of the future generations. I would encourage a 15-year-old me to be enthusiastic, confident, and authentic. It is also vital to avoid dwelling on past mistakes, because regret robs you of joy. The best decision I ever made was embracing Education and making sure that I was not only certified but learned to empower others in a humble way.” 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

“Although I am also inspired by Maya Angelou’s poem Still I rise, my mother is my biggest inspiration. She always had a smile on her face no matter how hard she worked, and she loved everyone. Her greatest strength is her ability to let nothing and no one remove her crown: ‘Strong winds may blow, but a QUEEN will bobby pin that thang in place and persevere because she is more than a conqueror’.”

“I am also inspired by the united force of women from all walks of life who, through a mass demonstration, marched to the Union Buildings in Pretoria on 9 August 1956, protesting against the unjust pass laws enforced on women in South Africa. This is in line with the 2020 Women's History Month theme, Valiant Women of the Vote. The theme honours the brave women who fought to win suffrage rights for women, and for the women who continue to fight for the voting rights of others. I SALUTE ALL WOMEN!

Wathint' Abafazi, Wathint' Imbokodo / You Strike A Woman, You Strike A Rock!!!!

 

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept